Parameter | Annual probability | |||
---|---|---|---|---|
 | HIV- subpopulation | Source | HIV+ subpopulation | Source |
Mortality rate | ||||
 General mortality rate | Age 15: 0.09 % | [65] | Age 15: 0.10 % | [65] |
Age 30: 0.20Â % | Age 30: 4.62Â % | |||
Age 45: 0.51Â % | Age 45: 7.71Â % | |||
Age 60: 1.56Â % | Age 60: 29.72Â % | |||
Age 75: 5.31Â % | Age 75: 37.38Â % | |||
HPV and HIV incidence | ||||
 HIV incidence rate in women | NA | - | Age 15: 0.025 | [65] |
Age 30: 0.004 | ||||
Age 45: 0.001 | ||||
Age 60: 0.001 | ||||
65+ years: 0 | ||||
 Oncogenic HPV incidence | 0.041–0.390 | [59] | 0.110–1.000 | |
Cervical cancer parameters | ||||
 Cervical cancer mortality | 0.110 | [2] | 0.291 | [67] |
 Cervical cancer cured | 0.151 | [2] | 0.027 | [67] |
HPV screening-related parameters | ||||
 Screening coverage | 13.6 % | [59] | 13.6 % | [59] |
 Screening ages | 30–60 years | [63] | 30–60 years | [63] |
 Screening frequency | Every 3 years | Every 3 years | ||
 CIN1 detected | 0.58 | [68] | 0.58 | [68] |
 CIN2/3 detected | 0.61 | [68] | 0.61 | [68] |
HPV-related disease management | ||||
 Proportion of women treated if CIN1 is detected | 0.50 | Assumption | 0.50 | Assumption |
 CIN1 treatment success | 0.90 | Assumption | 0.90 | Assumption |
 Proportion of women treated if CIN2/3 is detected | 1 | Assumption | 1 | Assumption |
 CIN2/3 treatment success | 0.90 | Assumption | 0.90 | Assumption |